Amgen Inc. v. Sanofi
Headline: Court rejects broad patents that claim all antibodies blocking PCSK9, upholding lower courts and making it harder for drugmakers to claim vast antibody families without detailed lab disclosure.
Holding:
- Limits drugmakers’ ability to claim broad antibody families without detailed lab instructions.
- Requires more disclosure for patents that cover many undisclosed antibodies.
- Makes it easier for competitors to avoid overly broad antibody patents.
Summary
Background
A biotechnology company (Amgen) and a competing drug company (Sanofi) each developed antibody drugs that lower “bad” LDL cholesterol by stopping a protein called PCSK9 from disabling the body’s LDL receptors. Amgen sought patents not for one specific antibody but for an entire group of antibodies that both bind to a particular PCSK9 area and block PCSK9’s harmful action. Amgen listed 26 example antibodies and described two methods—called a “roadmap” and “conservative substitution”—for finding other antibodies. Sanofi argued those broad claims were invalid because the patents did not teach others how to make and use the many antibodies the claims covered.
Reasoning
The Court asked whether Amgen’s patent disclosure actually enabled a qualified scientist to make and use the full class of antibodies Amgen claimed. Relying on long-standing patent principles, the Court said that claiming a wide class of things requires enough disclosure to enable the whole class, not just some examples. The Court found Amgen’s roadmap and substitution instructions were essentially trial-and-error research assignments and did not reliably teach how to produce all of the claimed antibodies. The Court affirmed the lower courts’ rulings that Amgen’s broader claims were not enabled.
Real world impact
The decision enforces that patents covering large families of antibodies must provide clearer, more specific laboratory guidance or narrower claims. Drug companies cannot rely on a few examples plus general testing steps to claim exclusive rights to vast, undisclosed antibody groups. This ruling favors greater disclosure and limits overly broad monopoly claims in antibody and biotech patenting.
Ask about this case
Ask questions about the entire case, including all opinions (majority, concurrences, dissents).
What was the Court's main decision and reasoning?
How did the dissenting opinions differ from the majority?
What are the practical implications of this ruling?